Day: May 27, 2022

On the 27th of May 2022 at 9:00 (EET) AB Klaipėdos nafta holds a conference webinar for its shareholders, investors, mass media representatives and other stakeholders. The presentation is held in English. The webinar is hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Mindaugas Kvekšas who will introduce the Group’s financial results for the three months of 2022 and will answer the participant questions. Webinar presentation is enclosed.Mindaugas Kvekšas, Chief Financial Officer, +370 46 391772AttachmentKN_activity results for_2022_Q1

AB Klaipėdos nafta (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and standalone financial results for three months ended 31 March 2022. Main financial indicators of the Group comparing 3 months of 2022 and 2021:  Financial results for 3 months of 2022 Change, compared to 3 months of 2021 Adjusted* results for 3 months of 2022 Change, compared to 3 months of 2021Revenue 17.9 million EUR +14.1% 17.9 million EUR +14.1%Net profit (loss) -2.8 million EUR +6.3 million EUR 1.4 million EUR +1.4 million EUREBITDA 8.4 million EUR +15.5% 8.4 million EUR +15.5%Main financial indicators of the Company comparing 3 months of 2022 and 2021:  Financial results for 3 months of 2022 Change, compared to 3 months of 2021 Adjusted* results for 3 months of 2022 Change, compared to 3 months of...

Moses Lake, Washington USA – May 27, 2022: REC Silicon ASA (REC Silicon) reported first quarter 2022 revenues of USD 34.6 million compared to USD 43.2 million in the fourth quarter of 2021. The Company also reported an EBITDA of USD 3.6M compared to a loss USD 0.4 million in the prior quarter. The Company reported EBITDA contributed by the semiconductor materials segment of USD 10.7 million for the first quarter compared to 9.3 million for the fourth quarter. The increase in EBITDA is due primarily to higher product sales prices and lower electricity costs compared to the fourth quarter of 2021. Silicon gas sales volumes for the fourth quarter were 764 MT compared to 750 MT during the prior quarter. Total polysilicon sales volumes for the quarter were 267 MT and polysilicon inventories increased by 103 MT. REC Silicon reported cash balances...

Regulated Information Nyrstar NV releases notice for the 2021 annual general shareholders’ meeting to be held on 28 June 2022 and provides a further update on the put option review process 27 May 2022 at 07.00 CEST Nyrstar NV (the “Company”) today issued the notice for the 2021 annual general shareholders’ meeting to be held on 28 June 2022 at 11:00 a.m. CEST. The annual general meeting will be held physically with no virtual option available. The practical modalities of the meeting are set out in the notice to the meeting which has been published on the Company’s website (https://www.nyrstar.be/en/investors/share-and-bondholder-information/shareholder-meetings). The full notice, including agenda, proposed resolutions and explanatory note can be found on the aforementioned Nyrstar website. Further, the Company provides an update...

WithSecure Corporation, Press Release, 27 May 2022, at 8:00 EEST WithSecure and F-Secure Capital Markets Day on 3 June 2022 WithSecure and F-Secure will arrange a Capital Markets Day for their analysts and investors on Friday 3 June 2022. WithSecure Capital Markets Day is held at 9 am to 12 pm EEST. The following persons are presenting:Juhani Hintikka, President and CEO (WithSecure) Antti Koskela, Chief Product Officer Ashley Clark, VP, Commercial (Solutions Business Unit) Janne Pirttilahti, VP, Cloud Protection Tom Jansson, Chief Financial OfficerF-Secure Capital Markets Day is held at 13 to 16 pm EEST. The following persons are presenting:Timo Laaksonen, CEO (F-Secure) Toby White, Chief Technology Officer Sari Somerkallio, Chief Financial OfficerBoth events are available via direct webcast. Participants will have an opportunity...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 27, 2022 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the outcome of a small Phase 2a feasibility study of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its objectives. Dipraglurant is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM. “While not showing conclusive effects of dipraglurant in this first study of an mGlu5NAM in blepharospasm patients, it has provided us with a number of important insights related to the patient population. These include clinical rating scales and novel objective measuring devices that will help to inform us for future development”,...

Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma 1 Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma Glofitamab is part of Roche’s industry-leading CD20xCD3 bispecific antibody development programme, which aims to address the diverse needs and preferences of people with blood cancersBasel, 27 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and...